Send us a text

Join us as we discuss the frontline therapy of metastatic hormone sensitive  prostate cancer with Professor Alison Birtle.
Alison has been involved in many of the key trials in urological cancers and shares her take on selecting patients for triplet therapy.
We also look at the factors that affect treatment choices for our mHSPC pateints.
This area has changed so much in recent years and Alison brings those changes to life in this episode.

You hope you enjoy!
John & Mike